1B-LSD: Difference between revisions

Line 6:

The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.

[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.

[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a prodrug for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.

@@ Line 6: / Line 6: @@
 The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market.
-[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.
+[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a prodrug for LSD.<ref name=":1">Wagmann, Lea, et al. "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures." ''Analytical and bioanalytical chemistry'' 411.19 (2019): 4751-4763.https://doi.org/10.1007/s00216-018-1558-9</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration.
 Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance.